Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Influences on the start, selection and duration of treatment with antibiotics in long-term care facilities.

Daneman N, Campitelli MA, Giannakeas V, Morris AM, Bell CM, Maxwell CJ, Jeffs L, Austin PC, Bronskill SE.

CMAJ. 2017 Jun 26;189(25):E851-E860. doi: 10.1503/cmaj.161437.

2.
3.

Sex differences in the outcomes of peripheral arterial disease: a population-based cohort study.

Hussain MA, Lindsay TF, Mamdani M, Wang X, Verma S, Al-Omran M.

CMAJ Open. 2016 Mar 30;4(1):E124-31. doi: 10.9778/cmajo.20150107. eCollection 2016 Jan-Mar.

4.

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.

Coeck N, de Jong BC, Diels M, de Rijk P, Ardizzoni E, Van Deun A, Rigouts L.

J Antimicrob Chemother. 2016 May;71(5):1233-40. doi: 10.1093/jac/dkv499. Epub 2016 Feb 6.

5.

Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis.

Blower TR, Williamson BH, Kerns RJ, Berger JM.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1706-13. doi: 10.1073/pnas.1525047113. Epub 2016 Jan 20.

6.

Update on the prevention and treatment of endophthalmitis.

Schwartz SG, Flynn HW Jr.

Expert Rev Ophthalmol. 2014 Oct;9(5):425-430. Epub 2014 Aug 23.

7.

Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJ, Hossain MA, Fissette K, Rieder HL, Meehan CJ, de Jong BC, Van Deun A.

J Antimicrob Chemother. 2016 Feb;71(2):314-23. doi: 10.1093/jac/dkv360. Epub 2015 Nov 24.

8.

Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study.

Daneman N, Lu H, Redelmeier DA.

BMJ Open. 2015 Nov 18;5(11):e010077. doi: 10.1136/bmjopen-2015-010077.

9.

Prescription Stimulant Use and Hospitalization for Psychosis or Mania: A Population-Based Study.

Cressman AM, Macdonald EM, Huang A, Gomes T, Paterson MJ, Kurdyak PA, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network.

J Clin Psychopharmacol. 2015 Dec;35(6):667-71. doi: 10.1097/JCP.0000000000000406.

10.

Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study.

Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, Paterson JM, Juurlink DN.

CMAJ Open. 2015 Apr 2;3(2):E166-71. doi: 10.9778/cmajo.20140074. eCollection 2015 Apr-Jun.

11.

Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM.

Clin Microbiol Rev. 2015 Oct;28(4):901-37. doi: 10.1128/CMR.00002-15. Review.

12.

A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.

Cressman AM, Macdonald EM, Fernandes KA, Gomes T, Paterson JM, Mamdani MM, Juurlink DN; Canadian Drug Safety Effectiveness Research Network (CDSERN).

Br J Clin Pharmacol. 2015 Oct;80(4):662-9. doi: 10.1111/bcp.12682. Epub 2015 Jul 2.

13.

Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study.

Antoniou T, Yao Z, Camacho X, Mamdani MM, Juurlink DN, Gomes T.

Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):256-61. doi: 10.1002/pds.3761. Epub 2015 Feb 5.

14.

A study on drug safety monitoring program in India.

Ahmad A, Patel I, Sanyal S, Balkrishnan R, Mohanta GP.

Indian J Pharm Sci. 2014 Sep;76(5):379-86. Review.

15.

Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study.

Zipursky J, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Paterson JM, Lathia N, Juurlink DN.

PLoS Med. 2014 Sep 30;11(9):e1001736. doi: 10.1371/journal.pmed.1001736. eCollection 2014 Sep.

16.

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium.

N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426. Epub 2014 Sep 7.

17.

Extended-release nifedipine and the risk of intestinal obstruction: a population-based study.

Juurlink DN, Hellings C, Gomes T, Huang A, Paterson JM, Urbach DR, Mamdani MM; Canadian Drug Safety and Effectiveness Research Network (CDSERN).

BMJ Open. 2014 Jul 24;4(7):e005377. doi: 10.1136/bmjopen-2014-005377.

18.

Operative trends and physician treatment costs associated with Dupuytren's disease in Canada.

Liu W, O'Gorman DB, Gan BS.

Can J Plast Surg. 2013 Winter;21(4):229-33.

19.

Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial.

Koirala S, Basnyat B, Arjyal A, Shilpakar O, Shrestha K, Shrestha R, Shrestha UM, Agrawal K, Koirala KD, Thapa SD, Karkey A, Dongol S, Giri A, Shakya M, Pathak KR, Campbell J, Baker S, Farrar J, Wolbers M, Dolecek C.

PLoS Negl Trop Dis. 2013 Oct 31;7(10):e2523. doi: 10.1371/journal.pntd.0002523. eCollection 2013.

20.

Statins and the risk of herpes zoster: a population-based cohort study.

Antoniou T, Zheng H, Singh S, Juurlink DN, Mamdani MM, Gomes T.

Clin Infect Dis. 2014 Feb;58(3):350-6. doi: 10.1093/cid/cit745. Epub 2013 Nov 13. Erratum in: Clin Infect Dis. 2014 Apr;58(8):1203.

Supplemental Content

Support Center